AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts ...

Expectations for the full year Core tax rate are unchanged at 18-22% Core EPS increased 21% to $2.49 Five positive Phase III readouts and 13 approvals in major regions since the prior results Pascal ...

AstraZeneca is bolstering its US manufacturing presence as President Donald Trump's White Hulls mulls the imposition of fresh ...

Pascal Soriot, Chief Executive Officer, AstraZeneca, said ... leveraging our two large R&D sites in Gaithersburg MD and Cambridge MA. Overall, we are making excellent progress toward our ambition ...

In Q1 2025, total revenue jumped 10 per cent to $13.5bn, driven by double-digit growth in Oncology and BioPharmaceuticals The ... leveraging our two large R&D sites in Gaithersburg MD and Cambridge MA ...

Class of 2025 received their Doctor of Pharmacy degrees Saturday during the college’s 18th commencement exercises.

AstraZeneca (AZ) has poached Sean Bohen from Genentech to take the lead role in late stage development of its pipeline drugs. Sean Bohen MD, PhD is ... new medicines in oncology alone by 2020.

As it applies to the development of cell therapies, AstraZeneca’s chief of global operations, Pam Cheng, admits that the ...